Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.

Autor: Palanca-Wessels MC; Clinical Research Division and Center for Intracellular Delivery of Biologics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Hematology Division, University of Washington, Seattle, WA, USA., Booth GC; Clinical Research Division and Center for Intracellular Delivery of Biologics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Convertine AJ; Department of Bioengineering and Center for Intracellular Delivery of Biologics, University of Washington, Seattle, WA, USA., Lundy BB; Department of Bioengineering and Center for Intracellular Delivery of Biologics, University of Washington, Seattle, WA, USA., Berguig GY; Department of Bioengineering and Center for Intracellular Delivery of Biologics, University of Washington, Seattle, WA, USA., Press MF; Department of Pathology, University of Southern California, Los Angeles, CA, USA., Stayton PS; Department of Bioengineering and Center for Intracellular Delivery of Biologics, University of Washington, Seattle, WA, USA., Press OW; Clinical Research Division and Center for Intracellular Delivery of Biologics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Bioengineering and Center for Intracellular Delivery of Biologics, University of Washington, Seattle, WA, USA.

Publikováno v: Oncotarget [Oncotarget] 2016 Feb 23; Vol. 7 (8), pp. 9561-75.